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Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disorder with a wide range of motor and non-motor
symptoms. Despite optimal medical management, PD still results in a high disability rate and secondary complications
and many patients lead a sedentary lifestyle, which in turn is also associated with a higher co-morbidity and mortality.
Exercise has been explored as a strategy to reduce secondary complications and results suggests that it not only
provides general health benefits, but may also provide symptomatic relief. If this holds true exercise would be
a very attractive addition to the therapeutic arsenal in PD. The supportive evidence remains incomplete. Here,
we describe the design of the Park-in-Shape study, which primarily aims to evaluate whether aerobic exercise
affords clinically relevant improvements in motor symptoms in sedentary PD patients. A specific new element
is the introduction of gaming to optimize compliance to the exercise intervention.
Methods/Design: The Park-in-Shape study is a randomized controlled, assessor- and patient-blinded single
center study. Two parallel groups will include a total of 130 patients, receiving either aerobic exercise on a
home trainer equipped with gaming elements (“exergaming”), or a non-aerobic intervention (stretching, flexibility
and relaxation exercises). Both groups are supported by a specifically designed motivational app that uses gaming
elements to stimulate patients to exercise and rewards them after having completed the exercise. Both interventions
are delivered at home at least 3 times a week for 30–45 minutes during 6 months. Eligible patients are
community-dwelling, sedentary patients diagnosed with mild-moderate PD. The primary outcome is the MDS-UPDRS
motor score (tested in the off state) after 6 months. Secondary outcomes include various motor and non-motor
symptoms, quality of life, physical fitness, and adherence.
Discussion: This Park-in-Shape study is anticipated to answer the question whether high intensity aerobic
exercise combined with gaming elements (“exergaming”) provides symptomatic relief in PD. Strong elements
include the double-blinded randomized controlled trial design, the MDS-UPDRS as valid primary outcome, the
large sample size and unique combination of home-based pure aerobic exercise combined with gaming
elements and motivational aspects.
Trial registration: Dutch trial register NTR4743
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Background
Despite optimal medical management, Parkinson’s disease
(PD) remains a disabling and costly neurodegenerative
disease in current clinical practice. The disease-related
motor and non-motor symptoms largely determine the
patients’ disability and therefore their quality of life. In
addition many PD patients lead a sedentary lifestyle due
to these symptoms, resulting in a higher co-morbidity and
mortality. Additional strategies that reduce these symp-
toms as well as their secondary complications are needed
to expand the patients’ functional ability, optimize inde-
pendence and improve quality of life. Over the last de-
cades exercise has been explored as such a strategy and
has shown promising results, with positive effects on gen-
eric health benefits as well as on disease-related symptoms
[1-3]. Studies in animal models of PD have demonstrated
that high-intensity exercise can provide symptomatic relief
of parkinsonian signs [4]. Similar results were seen in
small treadmill studies in PD patients, showing improve-
ment in gait parameters and enhanced physical fitness
[5-7]. Perhaps even more fascinating are the observed
changes in the “parkinsonian” rodent striatum after aer-
obic exercise, including: (a) increased angiogenesis [8], (b)
decreased expression of brain damage markers [9], (c) de-
creased expression of the dopamine active transporter, (d)
increased D2 receptor mRNA levels and even (e) reversal
of dopaminergic cell loss [4,10,11]. Two recent small co-
hort studies in PD patients show similar results following
high-intensive aerobic exercise. Specifically, postsynaptic
D2 receptor binding potential on PET imaging increased
[12] and cortical hyperexcitability (which is characteristic
for the parkinsonian state), as measured with transcranial
magnetic stimulation, reduced [13]. This suggests that in-
tensive aerobic exercise may promote adaptive plasticity
of the dopaminergic system, raising hopes that exercise
might change the course of PD. If this holds true, exercise
would be a very attractive addition to the therapeutic ar-
senal in PD.
Based on these promising results, (aerobic) exercise is
already widely advocated as symptomatic treatment in
current practice. However, the strength of the available
evidence remains limited, due to small sample sizes and
the uncontrolled or non-randomized nature of previous
research. In addition, heterogeneous interventions (type,
intensity and duration) and outcomes were used, making a
meta-analysis or systematic review challenging [2,3,14,15].
Finally, treatment compliance is major challenge in any
exercise study, particularly if the exercise should be main-
tained for long periods (up to many years) to achieve full
benefits.
Here, we describe the design of the Park-in-Shape study,
a controlled, assessor and patient-blinded single centre
study that addresses some of the aforementioned short-
comings. A specific new element is the introduction of
gaming to optimize compliance to the exercise interven-
tion, in three different ways: to motivate patients to begin
the exercise; to stimulate patients during the actual exer-
cise; and to reward patients after having completed the
exercise.
Objectives
The primary objective of the Park-in-Shape study is to
evaluate whether aerobic exercise can lead to clinically
relevant improvements in motor functioning in seden-
tary PD patients. The secondary objectives are to evalu-
ate whether aerobic exercise results in improvements in
other clinically relevant symptoms, physical fitness and
quality of life.
Methods/Design
Ethical approval and trial registration
The study is executed in compliance with the Helsinki
Declaration. The study protocol, patient information and in-
formed consent forms have been approved by the local eth-
ics committee (CMO Arnhem-Nijmegen; NL47747.091.14.).
Informed consent is signed at the beginning of the in-
person assessments, after the patient is fully informed
about the procedures. The Park-in-Shape trial is registered
in the Dutch trial registry (www.trialregister.nl registration
number NTR4743).
Study design
The Park-in-Shape study is a randomized controlled,
double-blinded study performed in a single center (Figure 1).
Patients are randomly assigned to the intervention (aer-
obic exercise) or the active control group (stretching), but
are unaware of the allocation possibilities. The assessors
performing the baseline and follow-up assessments (dir-
ectly after the intervention period of 6 months) are also
blinded for allocation. Motivational aspects are applied in
both groups to increase compliance (see below for further
details).
Study population
In- and exclusion criteria are shown in Table 1. Included
participants are community-dwelling patients with a sed-
entary lifestyle. All patients who performed none or insuf-
ficient aerobic physical activity according to the current
recommendations for of the American College of Sports
Medicine (ACSM) for older adults [16] (i.e. vigorous exer-
cise performed < 3 times a week, 20 minutes per session
or moderate exercise performed <5 times a week, 30 mi-
nutes per session) are considered to have a sedentary life-
style and are eligible. Furthermore, eligible patients are
aged between 30 and 75, have idiopathic PD diagnosed by
a neurologist (using the UK Brain Bank Criteria), with
Hoehn and Yahr stages I-II (tested in the off state) [17,18].
Both medicated and unmedicated patients are eligible.
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Medicated patients can only be included if they receive a
stable dopaminergic medication dose for at least one
month prior to inclusion in the study (levodopa and/or a
dopamine agonist are allowed). Unmedicated patients
are eligible if they are deemed unlikely to start treat-
ment within the next month, as judged by their treat-
ing neurologist.
Recruitment and setting
Participants will be recruited primarily through the
neurology department at the Radboud university medical
center (Radboudumc), Nijmegen, the Netherlands. Add-
itional centers in the vicinity of Nijmegen will be invited
to assist in the recruitment. The inclusion period will
last 2.5 years. Eligibility is established through telephone
Figure 1 Study designPark-in-shape.
Table 1 In- and exclusion criteria
Inclusion criteria Exclusion criteria
Idiopathic Parkinson’s disease diagnosed by a neurologist Medication:
• Beta-blockers and/or anti-psychotics
Hoehn & Yahr stage ≤2 (tested in off state) Comorbidity:
• Neurologic or orthopedic co-morbidities that make it impossible
to cycle or perform stretching exercises (safely)
• Contra-indications for aerobic exercise including diagnosed cardiac
diseases, diagnosed but poorly controlled diabetes
• mellitus or pulmonary diseases.
• Psychiatric diseases: major depressive disorder, severe or moderate
depressive episode or any form of psychosis), diagnosed by a
psychiatrist in the last year.
• Dementia: MMSE <24
Age 30–75 years Inability to fill out questionnaires or perform a computer task
(i.e. due to poor vision, inability to read Dutch (illiteracy or
foreign language))
Sedentary lifestyle [16] Facilities:
• No internet at home
Parkinson medication: Availability/compliance:
• Stable dopaminergic medication dose (both levodopa and/or a dopamine
agonist are allowed) for at least one month before the study
• Unavailable for more than 10% (approximately 2.5 weeks) of
the 6 months
• No treatment and deemed unlikely to start treatment within the next month
by their treating neurologist
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screening and in-person assessments. During the tele-
phone screening a trained research nurse interviews the
patients regarding their physical activity (LAPAQ out-
door and norms of the ACSM [16]), comorbidity, medi-
cation use, ability to complete questionnaires or perform
computer tasks, facilities at home and availability. If
there is no reason for exclusion at this stage, participants
are invited to the study site for in-person assessments.
In-person assessments take place in the Radboudumc
and include: (a) screening of cognitive function and dis-
ease stage (Hoehn & Yahr) without dopaminergic medi-
cation by a trained research nurse, (b) medical screening
by a cardiologist to rule out any medical conditions that
preclude endurance exercise; and (c) a maximal-graded
exercise test to determine the presence of serious arrhyth-
mias, evidence of ischemia or increases of diastolic blood
pressure above 115 mmHg or increases of systolic blood
pressure above 235 mmHg. Abnormalities observed dur-
ing the graded exercise test require follow-up by a cardi-
ologist to determine whether high-intensity exercise can
be performed safely. Informed consent is signed at the be-
ginning of the in-person assessments. If no exclusion cri-
teria are met during the in-person assessments, patients
are included and baseline measurements are performed.
Randomization and blinding
Within two weeks after informed consent is signed, partic-
ipants will be randomly assigned to one of the two groups
using a web-based system designed by an independent
statistician. The allocation ratio is 1:1 and the procedure
entails permuted blocks of varying sizes (unknown to the
study personnel). Minimization is performed for gender
and medication status (treated/untreated). The patients,
all study personnel involved in the screening and assess-
ments and the researcher who will analyze the data will be
blinded for the allocation. Randomization is performed by
a member of the research team who is not involved in the
assessments or the data analysis. Patients will be informed
of their allocation after randomization by the coach (see
below) but are unaware of the details of the two allocation
possibilities. Blinding of patients will be checked after the
patient has finished his/her participation by asking them
whether they felt their prescribed program was effective.
Measurements
Assessments will be performed at baseline and after
6 months. All measurements are only performed in off
state, except for the maximal graded exercise test which
is performed in the on state and in the UPDRS III, which
is performed in both the off state (primary outcome)
and in the on state (secondary outcome). The maximal-
graded exercise test is performed in on state for two rea-
sons: 1) to minimize any PD related motor limitations,
allowing for a maximal cardiovascular performance, and
2) because patients are also instructed to train during their
participation in the study in their optimal therapeutic state
(on state) and the training intensity will be based on the
maximal heart rate determined in the maximal graded ex-
ercise test. Off state is determined as >12 hours after the
last Parkinson medication intake (and if applicable: deep
brain stimulation switched off during the measurements).
Therefore all patients are asked to skip the morning dose
of their Parkinson medication at the day of the assess-
ment. All assessments will start at the same time of the
day and will be performed in the same sequence, minimiz-
ing the difference in time spent in the off state between
participants. At the end of the assessment, the two afore-
mentioned tests are performed in the on state. On state is
determined by 1 hour after taking a supra-threshold dose
of their morning medication (125% of their morning levo-
dopa equivalent dose (LED) for levodopa [19,20]). Half an
hour before their lunch, patients are instructed to take this
supra-threshold dose to ensure that they reach an on state
that is equivalent to their everyday functioning, and that
persists throughout the on state assessments. All tests and
questionnaires used are described in Table 2 and are de-
tailed here below.
General variables
The following data are collected at baseline: age at base-
line, gender, education, age at onset and disease dur-
ation. Details on Parkinson medication (i.e., drug name,
dose, frequency, levodopa equivalence) will be collected
during both visits using a customized form.
Primary outcome measure
The primary outcome will be the score on the motor
section of the Movement Disorders Society-sponsored
revision of the Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) [18] after 6 months measured in the off
state. The UDPRS is the most widely used, well-validated,
clinical rating scale for PD and has been shown to be sen-
sitive to change in clinical status [21] and data on clinical
important differences are available [22,23]. Based on these
data we considered a change of minimal 3.5 clinically im-
portant. Clinical progression appears to be faster and
UPDRS motor score increases steeper in early stages of
PD [24-26], underlining the need for treatments that can
reduce the UPDRS motor score in these stages and slow
down the disability rate. As intra-rater variability is lower
compared to inter-rater variability [27] the same rater will
perform the MDS-UDPRS-III assessments at baseline and
follow up.
Secondary outcome measures
Additional motor symptoms To test the impact of the
intervention on motor symptoms during everyday life,
the MDS-UPDRS III is also assessed in the on state.
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Table 2 Study schedule and assessments
t = wk 0 t = wk 1-2 t = wk 2-3 t = wk 26-27 t = wk 27-28
Activity/Assessment Pre-study screening
(phone)
Study visit 1
(Screening/Baseline)
@ home Study visit 2
(post-intervention)
@ home
Inclusion/Exclusion criteria
Cardiovascular risk factors
Rose questionnaire x
Physical exam & ECG x x
MMSE x
LAPAQ outdoor x
H&Y stage x x
Primary outcome
Motor symptoms
MDS-UPDRS III off x x
Secondary outcomes
Motor symptoms
MDS-UPDRS III on x x
MDS-UPDRS IV x x
TUG x x
Pegboard x x
Finger tap test x x
Mini-BESTest x x
Falls & Near-falls x x
Non-motor symptoms
TAP flexibility x x
TMT x x
MoCa x x
SCOPA-sleep x x
HADS x x
SCOPA-AUT x x
FSS x x
Quality of life
PDQ-39 x x
Physical fitness
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Table 2 Study schedule and assessments (Continued)
VO2max x x
6MWT x x
Adherence
Bike computer/motivational app data Data is automatically collected after each workout on a secured
server. After 6 months the data is archived and locked.
ECG = electrocardiogram. MMSE =Mini Mental State Examination, LAPAQ= Longitudinal aging study Amsterdam Physical Activity Questionnaire. H&Y =Hoehn & Yahr, MDS-UPDRS III/IV =Movement Disorders Society-sponsored
revision of the Unified Parkinson’s Disease Rating Scale, motor section (III) and motor complications section (IV). TUG = Timed Up and Go test. Mini-BESTets = Mini-Balance Evaluation System Test. TAP = Test of
Attentional Performance. TMT = Trial Making Test. MoCa = Montreal Cognitive Assessment. SCOPA-sleep = SCales for Outcomes in PArkinson’s disease, sleep section. SCOPA-aut = SCales for Outcomes in
PArkinson’s disease, autonomic function section. FSS = Fatigue Severity Scale. PDQ-39 = 39-item Parkinson Disease Questionnaire VO2max = maximal amount of oxygen inhaled during maximal graded test.
6MWT = 6 Minute Walk Test.
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Balance deficits will be analyzed with the short version
of the Balance Evaluation System Test (Mini-BESTest).
The Mini-BEST test is a clinical tool that is highly corre-
lated with the validated and generally accepted Berg
Balance Scale, but is more suitable for mild PD as it has
no ceiling effect [28]. Balance impairment is defined as a
score of ≥21 on the Mini-BESTest [29]. The Timed Up
and Go test (TUG) will be used to test mobility. The TUG
measures the ability of patients to perform sequential
locomotor tasks that incorporate walking and turning. It
has been validated in PD and is sensitive to changes in
mobility in PD patients [30]. The Dexterity device of the
Objective Parkinson’s Disease Measurement system will
be used to quantify bradykinesia with a digitography (key-
board) test, and complex motor functioning is tested with
a pegboard test.
Motor complications and (near) falls will be assessed by
questionnaires. Falls and near-falls will be registered retro-
spectively over a period of 6 months with an interview-
based questionnaire that is used in clinical practice by
physiotherapist specialized in PD [31]. Even patients with
early disease may already experience fluctuations in their
response to levodopa [32]. Therefore, motor complica-
tions will be evaluated as well, using the interview-based
MDS-UPDRS IV questionnaire.
Non-motor symptoms Several studies report beneficial
effects of aerobic exercise on cognitive function in healthy
elderly [33]. During the in-person assessments several
cognitive tests will be performed. The Montreal Cognitive
Assessment scale (MoCa) is used for a quick screening of
global cognitive function. It has been widely accepted for
use in PD populations [34] by assessing multiple domains
of cognitive function including memory, language, com-
plex visuospatial processing, and executive function. The
MoCa is suggested to be more sensitive to cognitive im-
pairment in PD and to temporal changes compared with
the MMSE [35]. One of the earliest cognitive deficits in
PD is executive function (set-shifting in particular) [36].
We will perform two tests to assess set-shifting in off state:
the flexibility subset of the Test of Attentional Perform-
ance (TAP 3.2) and the Trail Making Test (TMT) A and
B. In the flexibility subset of the TAP test two verbal stim-
uli (letter-number) are simultaneously presented on a
computer screen and the patient has to press the button
on the side of the target stimulus. The target stimulus will
either be fixed (requiring a response to the side of letters
or numbers only) or alternating (requiring a response that
alternates between letters and numbers). A similar non-
computerized version of this task has been used before in
PD and shown to be highly specific for task-set shifting in
PD patients in off state [37]. The TMT is one of the most
frequently used paper and pencil test in clinical practice
and consists of two parts: one assessing psychomotor
speed (A) and one assessing mental flexibility (B) [38].
Also in PD the TMT is able to indicate deficits in set shift-
ing [39]. For all three cognitive tests parallel versions will
be used at follow up, to minimize learning effects.
Several studies in non-PD populations indicated bene-
ficial effects of aerobic exercise on mood [40,41], sleep
[42], constipation [43] and fatigue [44]; all of which are
part of the non-motor symptoms that PD patients may
experience. We will use self-rating questionnaires that
are completed at home to assess these non-motor symp-
toms. Mood will be assessed with the Hamilton Anxiety
and Depression Scale (HADS). This is a 14-item scale
assessing both depression and anxiety and has been vali-
dated in PD patients [45]. The section on sleep of the
Scales for Outcomes in Parkinson’s disease (SCOPA-
Sleep) will be used to measure sleep disturbances. This a
short practical self-rating scale designed to evaluate
sleep quality and daytime sleepiness [46]. Autonomic
symptoms can be assessed with the SCOPA-autonomic
(SCOPA-AUT) [47]. For the purpose of this trial only
the gastro-intestinal section of the SCOPA-AUT will be
used to assess constipation. Fatigue will be addressed by
the Fatigue Severity Scale (FSS), which has been recom-
mended for screening and severity rating in PD by the
movement disorders society [48].
Quality of life Quality of life will be assessed with the
39-item Parkinson Disease Questionnaire (PDQ-39), a PD
specific self-administered questionnaire [49]. Participants
are asked to fill out this questionnaire at home.
Physical fitness Physical fitness is measured using the 6-
minute walk test and the maximal aerobic power tested by
indirect calorimetry (VO2max) during the maximal graded
exercise test. The 6-minute walk test is widely used to as-
sess functional exercise capacity and normative values for
PD patients exist [50]. The VO2max is the gold standard
of cardiovascular fitness and is a reliable and repeatable
measure in subjects with mild to moderate PD [51].
Adherence Adherence will be determined based on the
number of dropouts and the training frequency in both
groups, as well as the total time exercised within the
prescribed heart rate zone in the intervention group.
Interventions
The total duration of the intervention will be 6 months,
regardless of group allocation. All patients will be sup-
ported by the same coach during their intervention.
Aerobic exercise (intervention group)
The intervention is multifaceted and consists of a unique
combination of home-based aerobic exercise, enhanced
with virtual reality software and real-life videos, the use
van der Kolk et al. BMC Neurology  (2015) 15:56 Page 7 of 12
of a motivational app and coaching with tele-monitoring
from a distance. Aerobic exercise, performed on a sta-
tionary home trainer, forms the basis of the intervention.
The home trainer is connected to an all-in-one com-
puter equipped with software (Simultrainer Europe Ltd.)
that provides visual feedback and virtual coaching (to-
gether with the aerobic workout, this combination is re-
ferred to as “exergaming”). Patients are instructed to
train at least 3 times a week for 30–45 minutes within a
predetermined heart rate zone. The heart rate zone is
based on the heart rate reserve (HRR), calculated with
the Karvonen method; the lower bound will gradually
increase from 50% to 70% of the HRR (the upper bound
is set at 80%). During the training session, the actual
heart rate and time exercised within the heart rate zone,
is visualized providing direct feedback. The software of-
fers the opportunity to (a) cycle classical bike routes ac-
companied by real-life videos of the route, (b) cycle in a
virtual world in which they can compete against their
own best previous performance or virtual competitors;
and (c) to perform an adjusted arcade game that is
driven by the patient’s cycling performance. Taken to-
gether, this serves to motivate the patients during the ac-
tual exercise.
In addition, we designed a customized tablet-based
motivational app (Park-in-Shape app, designed by IJsfon-
tein Interactive Media Ltd.) to motivate patients both be-
fore and after the actual exercise. Specifically, the app
shows exercise goals, provides support, and gives feed-
back about performance. Patients can view their results
in a comprehensible way and can invite supporters to
track their progress. Supporters can stimulate them to
reach their goals by cheering them on, complimenting
them on their performance, and promising incentives
when they reach one of their goals.
Every fortnight a coach will have telephone contact
with the participants to check their progress, to adjust
their training schedule (if necessary) and to provide sup-
port. At least every 4 weeks the training schedules are
evaluated and if the patient was easily able to adhere to
the prescribed heart rate zone, the heart rate zone is
raised. This allows for a graded increase in the aerobic
exercise and offers a reward system by setting goals. The
coach can decide on the individual intervals of these fit-
ness checks. Communication between the bike computer
and the motivational app ensures that adjustments in ex-
ercise goals are immediately and correctly enforced. Data
from the training sessions are automatically saved after
each session and uploaded to a secured server, allowing
the coach to track the progress from a distance.
Stretching (active control)
The control condition is designed as an ‘active control’
to increase compliance, and consists of stretching,
flexibility and relaxation exercises. The exercises do not
have an aerobic component and are based on previous
studies in which stretching served as a control [52,53].
The core activities encompass stretches involving the
upper body and lower extremities, with the use of gentle
joint extension and flexion and trunk rotation. In
addition abdominal breathing with an emphasis on in-
haling and exhaling to maximum capacity and relaxation
of major muscles will be used. Patients are instructed to
do the exercises 3 times a week for approximately 30 mi-
nutes without adding other elements to the training (no
dumbbells, etcetera). After randomization, the app and
the first exercise program will be explained by the coach
during a home visit. The rest of the time the exercises
will be executed unsupervised within the patients’ home.
These exercises are commonly given to patients by the
patients’ physiotherapists without specific supervision,
and the majority of the exercises will be performed in
seated or supine position reducing the fall risk.
In order to increase comparability between the two
groups, the active control group will also be supported
and motivated by the coach using the same protocol as
in the intervention group. This includes an adjusted ver-
sion of the motivational app for the active control group.
Exercises are explained in the app through text and vid-
eos, and every month a different set of exercises will be
presented. Patients will note the frequency of the per-
formed exercises in the app, allowing the coach to follow
the performance of the patients on a distance. Moreover
the coach can tailor the program to the individual needs.
Drop-outs and adverse events
Patients who drop out will be encouraged to complete
the follow-up measurements. All adverse events will be
noted in the electronic database; in case of serious ad-
verse events the responsible authorities will be notified
immediately.
Medication adjustments
During participation, no adjustments will be made in the
Parkinson medication by the research team, and partici-
pants are asked to keep their medication stable during
the intervention period. However, if medication changes
are deemed necessary by the treating neurologist, they
are allowed to do so. Any changes in medication will be
noted in the patient’s case record form.
Power and sample size estimate
Our study is powered to show an effect of moderately-
high intensive aerobic exercise on the MDS-UPDRS
motor score after 6 months. For this, data on the ex-
pected effect size of the intervention (change in UPDRS
motor score over 6 months with moderately intensive
exercise (and standard deviation) compared to controls)
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is needed. We have performed a pilot study in 21 seden-
tary PD patients, of whom 11 were randomized to per-
form moderately intensive aerobic exercise for 6 months.
The rest served as controls. The control group had an
increase in UPDRS motor score of approximately 6.5
whereas the exercise group increased approximately 1.5
points over 6 months. This results in a difference of
5 points between the groups. The standard deviation of
the follow-up measurement was approximately 9.
A clinical important difference for the within-patient
change in UPDRS motor score is described in two stud-
ies and varies between 2.5-10.8 points [22,23]. Based on
a combination of distribution-based and a triple anchor-
based approach a minimal effect size was established at
2.5 points change, a moderate effect size at 5.2 points
and a large effect size at 10.8 points change in moder-
ately severe PD (H&YI-III) [23]. The influence of disease
severity on the clinically important difference remains
unclear. However the patient population represented in
the MCID studies is similar to our study population,
whereas the patients in our pilot where mainly early PD
patients. Therefore we assumed a minimal difference be-
tween the control and the intervention group at 6 months
on the MDS-UPDRS motor score of 3.5 points for the
power analysis. Based on an effect size of 3.5 points, a
standard deviation of 9 and a two sided α of 0.05, a sample
size of n = 105 per group will be needed to obtain a power
of 80%.
However, we will perform an ANCOVA analysis in
which the baseline measurement will serve as a covari-
ate. As previously described, a correction for the correl-
ation between the baseline and follow-up scores should
be made [54]. In our pilot study the correlation (r) was
0.7, resulting in n = 53 patients per group (105 × (1-r2)).
Adherence rates in previous moderately-high intensive
exercise studies were around 80% [6,55,56]. In our pilot
study all patients completed the intervention; however
81.4% of all exercised time was performed within the pre-
scribed intensity. Therefore an attrition rate of between
18-20% was deemed reasonable, resulting in n = 65 pa-
tients per group.
Data collection and management
Prior to data collection, study personnel will review the
standard operating procedures (SOP) protocol manual.
Assessors will be trained and certified in Good Clinical
Practice (GCP) and in performing the MDS-UPDRS ac-
cording to the guidelines of the Movement Disorder
Society. Moreover they will be trained in the other as-
sessments by experienced raters and will rate at least
two persons with PD together with an experienced rater.
At each measurement interval, data will be collected on
paper forms and entered into a web-based data entry
portal by the research nurse. Questionnaires are sent by
email to the patients and are immediately imported in
the electronic database after they are completed. Stored
data will be backed up daily. Authenticated investigators
will have access to the dataset from any internet access
point. Monitoring of the study procedures and progress
of the inclusion will be performed by a member of the
hospital’s research center, who is not involved in the
study. After completion of the study the database will be
validated and locked before data-analysis is initiated.
Statistical analysis plan
The primary and secondary outcomes will all be analyzed
with an analysis of covariance (ANCOVA). The dependent
variable will be the follow up scores; group allocation, gen-
der and treatment status will serve as fixed factors and the
baseline values, age at baseline, Hoehn & Yahr stage, dis-
ease duration will serve as covariates. The analyses will be
performed on an intention-treat basis. In case of any miss-
ing data, sensitivity analysis (last observation carried for-
ward) will be used with delta-adjusting imputation [57]. It
should be noted that both an improvement of symptoms
in the intervention group and a worsening of symptoms in
the control group are considered equally important given
the neurodegenerative nature of the disease. In order to
determine the optimal effect of aerobic exercise, an add-
itional per protocol analysis will be performed including
all patients who completed the program as prescribed.
Adherence to the program will be analyzed according to
intention-to-treat, but adherence to the prescribed heart
rate will be analyzed per-protocol as this is part of a medi-
ation analysis. Moreover dose-effect relationship will be
explored by calculating the correlation between the total
exercise volume and the delta score on the different out-
comes. An interim analysis will not be performed.
Discussion
Here we present the rationale and design of the Park-in-
Shape study, an RCT that aims to provide evidence for
the efficacy of aerobic exercise combined with gaming
(exergaming) on PD-related symptoms. Previous studies
have suggested a positive effect of aerobic exercise on
several motor symptoms in PD patients. However, these
studies had several shortcomings, as they (a) were either
non-randomized/non-controlled or single-blind RCTs,
(b) had outcome measures that lacked clinical relevance,
(c) had small sample sizes, (d) included other elements
besides aerobic exercise, such as resistance or balance
training (heterogeneous interventions), or (e) were lab-
based, making it difficult to translate the results to
everyday life [3,15]. In this regard, strong elements of
the Park-in-Shape study include the double-blinded ran-
domized controlled design, the MDS-UPDRS as a valid
primary outcome, the large sample size and the unique
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combination of home-based pure aerobic exercise com-
bined with gaming elements and motivational aspects.
The double-blind character of the Park-in-Shape study
is unique and allows for an even distribution of placebo ef-
fects in both groups. Obviously, performing an exercise
trial in a double blinded fashion is only possible when an
active control group is included (which may dilute the
contrast with the exercise arm). An advantage to having
an active control is that this will likely increase compli-
ance and minimize drop-out rates in the control arm.
The UDPRS is the most commonly used outcome
measure in PD research and has been extensively vali-
dated. It directly measures clinically relevant symptoms
related to the patient’s disabilities and quality of life [58].
Clinically important change rates have been determined
for the motor section. It is, however directly influenced
by dopaminergic treatment. Therefore, it is essential to
determine the medication state in which the scale is ap-
plied. We deliberately chose to test our patients in the
off state, for the following reasons (for a recent discus-
sion on this topic in exercise trials see: [59]): (a) testing
in the off state will provide the best insight in the direct ef-
fect of the intervention on the disease itself, and is as such
more suitable for a phase II trial such as the present one;
(b) as both medicated and unmedicated patients are eli-
gible, testing solely in on state (i.e. medicated patients are
on, but unmedicated patients are basically off ) might skew
the results, as dopaminergic medication is known to have
a large effect on clinical rating scales like the UPDRS; (c)
with disease progression, the therapeutic window of the
dopaminergic medication narrows, resulting in frequent
and increasingly unpredictable response fluctuations. The
quality of the on state is therefore not fully predictable
and this hampers the before-after comparisons within pa-
tients. By testing in the off state, we hope to have better
comparability between the disease states before and after
the intervention.
The majority of RCTs that examined the effects of aer-
obic exercise on PD-related symptoms included fewer
than 25 patients per arm [15]. Based on our power ana-
lysis, these numbers would offer a power of only <50%.
The Park-in-Shape trial is adequately powered to find a
significant change in MDS-UDPRS-III score, even with
an attrition rate of 18%.
The intervention of the Park-in-Shape trial will provide
insight into the effects of aerobic exercise on PD-related
symptoms, but will also directly reveal its feasibility for im-
plementation into a real life environment. Exercise per-
formed in laboratories is much more difficult to translate
to daily life, and compliance is probably not comparable.
Performing exercise at home lowers the barrier for patients
to engage in exercise, but still requires a strong motivation
and discipline among participants. Because changes in ex-
ercise behavior are notoriously difficult to accomplish
[56,60,61], the intervention of the Park-in-Shape trial en-
tails several novelties compared to previous exercise inter-
ventions, all designed specifically to motivate patients to
comply with the exercise program. First, addition of virtual
reality and real life videos during cycling has not been used
before in PD patients to stimulate their compliance in a
home-based intervention. Interestingly, such enrichment
(i.e. adding complexity and difficulty) has been used in ex-
perimental animal models of PD and is considered a main
parameter for driving neuroplasticity [62,63]. Moreover,
enrichment and variation were considered important
aspects of a good exercise program by PD patients who
participated in an exercise trial [61]. This concept of com-
bining a cognitive stimulating virtual reality environment
and motor training to increase the exercise effect is cur-
rently being explored in other PD trials as well, including
by our group [64]. Compliance and inclusion in that trial,
however is hampered by the high-frequency visits to the
laboratory for the intervention. Second, we have added as-
pects of support, using fortnightly coaching by a medical
professional, immediate visualization of their results and
progress, as well as support by the patient’s family and
friends.
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